
CLAIMS

1. A compound of Formula I:



(I),

or a pharmaceutically acceptable salt, solvate, prodrug, stereoisomer, or tautomer thereof, wherein:

X is CR_X or N;

Y_4 is CR_4 or N;

Y_5 is CR_5 or N;

Y_7 is CR_7 or N, provided that no more than one of Y_4, Y_5, and Y_7 is N;

R_X, R_4, R_5, and R_7 each independently is H, C_1-C_6 alkyl, C_1-C_6 haloalkyl, or halogen;

m is 0, 1, 2, 3, or 4;

each R_3 is independently C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_1-C_6 alkoxy, C_1-C_6 haloalkoxy, OH, or halogen;

R_N is H or C_1-C_6 alkyl;

R_6 is R_6' or $(CH_2)_{1\text{-}3}$-R_6';

R_6' is heteroaryl comprising a 5- or 6-membered ring comprising a nitrogen atom and optionally additional 1 to 3 heteroatoms selected from N, O, and S, fused-ring heteroaryl comprising a 5- or 6-membered ring comprising a nitrogen atom and optionally additional 1 to 3 heteroatoms selected from N, O, and S and a 5- or 6-membered ring optionally comprising 1 to 4 heteroatoms selected from N, O, and S, or heterocyclyl comprising a 4- to 6-membered ring comprising a nitrogen atom and optionally additional 1 to 3 heteroatoms selected from N, O, and S, or C_6-C_{10} aryl, wherein the heterocyclyl, aryl, heteroaryl, or fused-ring heteroaryl is optionally substituted with one or more R_{61}; and

each R_{61} is independently

C_1-C_6 alkyl optionally substituted with one or more groups independently selected from heteroaryl comprising one or two 5- or 6-membered rings and 1 to 4 heteroatoms selected from N, O, and S, C_1-C_6 alkyl amino, di-C_1-C_6 alkyl amino, halogen, OH, amino, and C_6-C_{10} aryl, ,

C_1-C_6 alkoxy, C_1-C_6 haloalkoxy, C_1-C_6 alkyl amino, di-C_1-C_6 alkyl amino, OH, amino, NO_2, halogen, CN, =O,

$C(O)R_{62}$, $C(O)OR_{62}$, $C(O)NR_{63}R_{64}$,

L-heteroaryl comprising one or two 5- or 6-membered rings and 1 to 4 heteroatoms selected from N, O, and S, L-C_6-C_{10} aryl, L-C_3-C_6 carbocyclyl, or L-heterocyclyl comprising one or two 4- to 6-membered rings and 1 to 4 heteroatoms selected from N, O, and S, wherein the aryl, heteroaryl, carbocyclyl, or heterocyclyl is optionally substituted with one or more groups independently selected from:

C_1-C_6 alkyl, C_1-C_6 haloalkyl, $(CH_2)_{0-3}$-C_1-C_6 alkoxy optionally substituted with one or more substituents selected from halogen, C_1-C_6 alkyl amino, di-C_1-C_6 alkyl amino, and C_1-C_6 alkoxy, O-$(CH_2)_{0-3}$-C_3-C_6 carbocyclyl, O-$(CH_2)_{0-3}$-heterocyclyl comprising one or two 3- to 6-membered rings and 1 to 4 heteroatoms selected from N, O, and S, O-$(CH_2)_{0-3}$-C_6-C_{10} aryl, O-$(CH_2)_{0-3}$-heteroaryl comprising one or two 5- or 6-membered rings and 1 to 4 heteroatoms selected from N, O, and S, C_1-C_6 alkyl amino wherein alkyl is optionally substituted with one or more substituents selected from C_1-C_6 alkyl amino, di-C_1-C_6 alkyl amino, and C_1-C_6 alkoxy, di-C_1-C_6 alkyl amino wherein each alkyl is independently optionally substituted with one or more substituents selected from C_1-C_6 alkyl amino, di-C_1-C_6 alkyl amino, and C_1-C_6 alkoxy, OH, amino, NO_2, halogen, CN, =O, $N(R_N)C(O)R_{62}$, $N(R_N)C(O)OR_{62}$, $N(R_N)S(O)_2$-C_1-C_6 alkyl, $N(R_N)S(O)_2$-C_3-C_6 cycloalkyl, $S(O)_{1-2}NH(C_1$-C_6 alkyl), $S(O)_{1-2}N(C_1$-C_6 alkyl)$_2$, $S(O)_{0-2}$-C_1-C_6 alkyl, $C(O)R_{62}$, $C(O)OR_{62}$, $C(O)NR_{63}R_{64}$, $P(=O)(OR_{62})_2$, C_3-C_6 carbocyclyl, heterocyclyl comprising one or two 3- to 6-membered rings and 1 to 4 heteroatoms selected from N, O, and S, C_6-C_{10} aryl, and heteroaryl comprising one or two 5- or 6-membered rings and 1 to 4 heteroatoms selected from N, O, and S, wherein two of the substituent groups, together with the carbon atom(s) to which they are attached, may form C_5-C_6 carbocyclyl or heterocyclyl comprising a 5- or 6-membered

ring and 1 or 2 heteroatoms selected from N, O, and S and wherein the carbocyclyl or heterocyclyl is optionally substituted with one or more R_A, and wherein one or more hydrogen atoms in the substituent group may be replaced with one or more deuterium atoms,

wherein:

L is absent, or a linker selected from O, $(CR_{L1}R_{L2})_n$, O-$(CR_{L1}R_{L2})_n$, $(CR_{L1}R_{L2})_n$-O, and $S(O)_2$;

each R_{L1} and each R_{L2} is independently H, CH_3, CH_2CH_3, or $CH(CH_3)_2$, or R_{L1} and R_{L2}, together with the carbon atom to which they are attached, may form C(O), C_3-C_6 cycloalkyl, or heterocyclyl comprising a 4- to 6-membered ring comprising and 1 to 3 heteroatoms selected from N, O, and S, wherein one or more hydrogen atoms in any of R_{L1} and R_{L2} may be replaced with one or more deuterium atoms;


each R_A is independently halogen, OH, C_1-C_6 alkyl, C_1-C_6 alkoxy, C_1-C_6 alkyl amino, or di-C_1-C_6 alkyl amino; and

n is 1, 2, or 3; or


two R_{61}, together with the carbon atom(s) to which they are attached, may form C_4-C_{10} carbocyclyl, heterocyclyl comprising one 4- to 6-membered and 1 to 3 heteroatoms selected from N, O, and S, spiro- or fused-heterocyclyl comprising two 4- to 6-membered rings comprising 1 to 4 heteroatoms selected from N, O, and S, or C_6 aryl, wherein the carbocyclyl, heterocyclyl, spiro- or fused-heterocyclyl, or aryl is optionally substituted with one or more groups independently selected from C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_1-C_6 alkoxy, C_1-C_6 haloalkoxy, C_1-C_6 alkyl amino, di-C_1-C_6 alkyl amino, OH, amino, halogen, CN, and =O; and

each R_{62}, each R_{63}, and each R_{64} is independently H, C_1-C_6 alkyl, or C_1-C_6 haloalkyl.







2. The compound of claim 1, of any one of Formulae II-IX:



(II),





(III),


(IV),

(V),

(VI),

(VII),

(VIII), or

(IX),

or a pharmaceutically acceptable salt, solvate, prodrug, stereoisomer, or tautomer thereof.

3. The compound of claim 1 or 2, of Formula II or III:


(II) or

(III),

or a pharmaceutically acceptable salt, solvate, prodrug, stereoisomer, or tautomer thereof.

4. The compound of claim 1 or 2, wherein

(a) R_6' is heteroaryl comprising a 5- or 6-membered ring comprising a nitrogen atom and optionally additional 1 to 3 heteroatoms selected from N, O, and S, or fused-ring heteroaryl comprising a 5- or 6-membered ring comprising a nitrogen atom and optionally additional 1 to 3 heteroatoms selected from N, O, and S and a 5- or 6-membered ring optionally comprising 1 to 4 heteroatoms selected from N, O, and S, wherein the heteroaryl or fused-ring heteroaryl is optionally substituted with one or more R_{61};

(b) R_6' is fused-ring heteroaryl comprising a 5- or 6-membered ring comprising a nitrogen atom and optionally additional 1 to 3 heteroatoms selected from N, O, and S and a 5- or 6-membered ring optionally comprising 1 to 4 heteroatoms selected from N, O, and S, wherein the fused-ring heteroaryl is optionally substituted with one or more R_{61};

(c) R_6' is C_6-C_{10} aryl optionally substituted with one or more R_{61}; or

(d) R_6' is heterocyclyl comprising a 5- or 6-membered ring comprising a nitrogen atom and optionally additional 1 to 3 heteroatoms selected from N, O, and S, wherein the heterocyclyl is optionally substituted with one or more R_{61}.

5. The compound of claim 4, wherein

(a) R_6' is heteroaryl comprising a 5-membered ring comprising a nitrogen atom and optionally additional 1 to 3 heteroatoms selected from N, O, and S, wherein the heteroaryl is optionally substituted with one or more R_{61}; or

(b) R_6' is fused-ring heteroaryl comprising a 5-membered ring comprising a nitrogen atom and optionally additional 1 to 3 heteroatoms selected from N, O, and S and a 5- or 6-membered ring optionally comprising 1 to 4 heteroatoms selected from N, O, and S, wherein the fused-ring heteroaryl is optionally substituted with one or more R_{61}.

6. The compound of claim 4, wherein at least one R_{61} is

C_1-C_6 alkyl optionally substituted with one or more groups independently selected from C_1-C_6 alkyl amino, di-C_1-C_6 alkyl amino, halogen, OH, amino, C_6-C_{10} aryl, and heteroaryl comprising one or two 5- or 6-membered rings and 1 to 4 heteroatoms selected from N, O, and S,

C_1-C_6 alkoxy, C_1-C_6 haloalkoxy, C_1-C_6 alkyl amino, di-C_1-C_6 alkyl amino, OH, amino, NO_2, halogen, CN, =O,

$C(O)R_{62}$, $C(O)OR_{62}$, $C(O)NR_{63}R_{64}$,

L-C_6-C_{10} aryl, L-heteroaryl comprising one or two 5- or 6-membered rings and 1 to 4 heteroatoms selected from N, O, and S, L-C_3-C_6 carbocyclyl, or L-heterocyclyl comprising one or two 4- to 6-membered rings and 1 to 4 heteroatoms selected from N, O, and S, wherein the aryl, heteroaryl, carbocyclyl, or heterocyclyl is optionally substituted.

7. The compound of claims 6, wherein at least one R_{61} is

C_1-C_6 alkyl optionally substituted with one or more groups independently selected from C_1-C_6 alkyl amino, di-C_1-C_6 alkyl amino,

halogen, OH, amino, C_6-C_{10} aryl, and heteroaryl comprising one or two 5- or 6-membered rings and 1 to 4 heteroatoms selected from N, O, and S,

C_1-C_6 alkoxy, C_1-C_6 haloalkoxy, C_1-C_6 alkyl amino, di-C_1-C_6 alkyl amino, OH, amino, NO_2, halogen, CN, =O,


$C(O)R_{62}$, $C(O)OR_{62}$, or $C(O)NR_{63}R_{64}$.

8. The compound of claim 6, wherein at least one R_{61} is L-C_6-C_{10} aryl, L-heteroaryl comprising one or two 5- or 6-membered rings and 1 to 4 heteroatoms selected from N, O, and S, L-C_3-C_6 carbocyclyl, or L-heterocyclyl comprising one or two 4- to 6-membered rings and 1 to 4 heteroatoms selected from N, O, and S, wherein the aryl, heteroaryl, carbocyclyl, or heterocyclyl is optionally substituted.

9. The compound of claim 8, wherein at least one R_{61} is L-C_6-C_{10} aryl or L-heteroaryl comprising one or two 5- or 6-membered rings and 1 to 4 heteroatoms selected from N, O, and S, wherein the aryl or heteroaryl is optionally substituted.

10. The compound of claim 4, wherein R_6' is substituted with two or more R_{61}, and at least two R_{61}, together with the carbon atom(s) to which they are attached, may form C_4-C_{10} carbocyclyl, heterocyclyl comprising one 4- to 6-membered and 1 to 3 heteroatoms selected from N, O, and S, spiro- or fused-heterocyclyl comprising two 4- to 6-membered rings comprising 1 to 4 heteroatoms selected from N, O, and S, or C_6 aryl, wherein the carbocyclyl, heterocyclyl, spiro- or fused-heterocyclyl, or aryl is optionally substituted with one or more groups independently selected from C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_1-C_6 alkoxy, C_1-C_6 haloalkoxy, C_1-C_6 alkyl amino, di-C_1-C_6 alkyl amino, OH, amino, halogen, CN, and =O.

11. The compound of claim 1, of Formula Ia:



(Ia),

or a pharmaceutically acceptable salt, solvate, prodrug, stereoisomer, or tautomer thereof, wherein:

X is CR_X or N;

R_X, R_4, R_5, and R_7 each independently is H, C_1-C_6 alkyl, C_1-C_6 haloalkyl, or halogen;

R_{61}' is

H,

C_1-C_6 alkyl optionally substituted with one or more groups independently selected from C_1-C_6 alkyl amino, di-C_1-C_6 alkyl amino, halogen, OH, amino, C_6-C_{10} aryl, and heteroaryl comprising one or two 5- or 6-membered rings and 1 to 4 heteroatoms selected from N, O, and S,

C_1-C_6 alkoxy, C_1-C_6 haloalkoxy, C_1-C_6 alkyl amino, di-C_1-C_6 alkyl amino, OH, amino, NO_2, halogen, CN,

$C(O)R_{62}$, $C(O)OR_{62}$, or $C(O)NR_{63}R_{64}$;

R_{62}, R_{63}, and R_{64} each independently is H, C_1-C_6 alkyl, or C_1-C_6 haloalkyl;

R_{L1} and R_{L2} each independently is H, CH_3, CH_2CH_3, or $CH(CH_3)_2$, or R_{L1} and R_{L2}, together with the carbon atom to which they are attached, may form C(O), C_3-C_6 cycloalkyl, or heterocyclyl comprising a 4- to 6-membered ring comprising and 1 to 3 heteroatoms selected from N, O, and S, wherein one or more hydrogen atoms in any of R_{L1} and R_{L2} may be replaced with one or more deuterium atoms;

X_1 is N or CR_{X1};

X_2 is N or CR_{X2};

X_3 is N or CR_{X3};

X_4 is N or CR_{X4};

X_5 is N or CR_{X5}, provided that no more than four of X_1, X_2, X_3, X_4, and X_5 are N;

R_{X1}, R_{X2}, R_{X3}, R_{X4}, and R_{X5} each independently is H, C_1-C_6 alkyl, C_1-C_6 haloalkyl, $(CH_2)_{0-3}$-C_1-C_6 alkoxy optionally substituted with one or more substituents selected from halogen, C_1-C_6 alkyl amino, di-C_1-C_6 alkyl amino, and C_1-C_6 alkoxy, O-$(CH_2)_{0-3}$-C_3-C_6 carbocyclyl, O-$(CH_2)_{0-3}$-heterocyclyl comprising one or two 3- to 6-membered rings and 1 to 4 heteroatoms selected from N, O, and S, O-$(CH_2)_{0-3}$-C_6-C_{10} aryl, O-$(CH_2)_{0-3}$-heteroaryl comprising one or two 5- or 6-membered rings and 1 to 4 heteroatoms selected from N, O, and S, C_1-C_6 alkyl amino wherein alkyl is optionally substituted with one or more substituents selected from C_1-C_6 alkyl amino, di-C_1-C_6 alkyl amino, and C_1-C_6 alkoxy, di-C_1-C_6 alkyl amino wherein each alkyl is independently optionally substituted with one or more substituents selected from C_1-C_6 alkyl amino, di-C_1-C_6 alkyl amino, and C_1-C_6 alkoxy, OH,

amino, NO_2, halogen, CN, =O, $N(R_N)C(O)R_{62}$, $N(R_N)C(O)OR_{62}$, $N(R_N)S(O)_2$-C_1-C_6 alkyl, $N(R_N)S(O)_2$-C_3-C_6 cycloalkyl, $S(O)_{1-2}NH(C_1$-C_6 alkyl), $S(O)_{1-2}N(C_1$-C_6 alkyl)$_2$, $S(O)_{0-2}$-C_1-C_6 alkyl, $C(O)R_{62}$, $C(O)OR_{62}$, $C(O)NR_{63}R_{64}$, $P(=O)(OR_{62})_2$, C_3-C_6 carbocyclyl, heterocyclyl comprising one or two 3- to 6-membered rings and 1 to 4 heteroatoms selected from N, O, and S, C_6-C_{10} aryl, and heteroaryl comprising one or two 5- or 6-membered rings and 1 to 4 heteroatoms selected from N, O, and S, wherein any two of R_{X1}, R_{X2}, R_{X3}, R_{X4}, and R_{X5} attached to adjacent carbon atoms, together with the carbon atoms to which they are attached, may form C_5-C_6 carbocyclyl or heterocyclyl comprising a 5- or 6-membered ring and 1 or 2 heteroatoms selected from N, O, and S and wherein the carbocyclyl or heterocyclyl is optionally substituted with one or more R_A, and wherein one or more hydrogen atoms in any of R_{X1}, R_{X2}, R_{X3}, R_{X4}, and R_{X5} may be replaced with one or more deuterium atoms; and

each R_A is independently halogen, OH, C_1-C_6 alkyl, C_1-C_6 alkoxy, C_1-C_6 alkyl amino, or di-C_1-C_6 alkyl amino.

12. The compound of claim 11, wherein R_{61}' is H or halogen.

13. The compound of claim 11, wherein R_{L1} and R_{L2} each independently is H, CH_3, CH_2CH_3, or $CH(CH_3)_2$.

14. The compound of claim 11, wherein

(a) X_1, X_2, and X_3 are each CH; or

(b) X_1 and X_2 are each N, and X_3 is CH; or


(c) X_2 and X_3 are each N, and X_1 is CH.

15. The compound of claim 11, wherein

(a) R_4 and R_7 each is H, and R_5 is H or F; or

(b) R_4 is F, and R_5 and R_7 are each independently H or F.

16. The compound of claim 1, of Formula Ib:



(Ib),

or a pharmaceutically acceptable salt, solvate, prodrug, stereoisomer, or tautomer thereof, wherein:

X is N or CR_X;

R_X, R_4, R_5, and R_7 each independently is H, C_1-C_6 alkyl, C_1-C_6 haloalkyl, or halogen;

each R_{61}" is independently

H,

C_1-C_6 alkyl optionally substituted with one or more groups independently selected from C_1-C_6 alkyl amino, di-C_1-C_6 alkyl amino, halogen, OH, amino, C_6-C_{10} aryl, and heteroaryl comprising one or two 5- or 6-membered rings and 1 to 4 heteroatoms selected from N, O, and S,

C_1-C_6 alkoxy, C_1-C_6 haloalkoxy, C_1-C_6 alkyl amino, di-C_1-C_6 alkyl amino, OH, amino, NO_2, halogen, CN,

$C(O)R_{62}$, $C(O)OR_{62}$, $C(O)NR_{63}R_{64}$,

L-C_6-C_{10} aryl, L-heteroaryl comprising one or two 5- or 6-membered rings and 1 to 4 heteroatoms selected from N, O, and S, L-C_3-C_6 carbocyclyl, or L-heterocyclyl comprising one or two 4- to 6-membered rings and 1 to 4 heteroatoms selected from N, O, and S, wherein the aryl, heteroaryl, carbocyclyl, or heterocyclyl is optionally substituted with one or more groups independently selected from:

C_1-C_6 alkyl, C_1-C_6 haloalkyl, $(CH_2)_{0-3}$-C_1-C_6 alkoxy optionally substituted with one or more substituents selected from halogen, C_1-C_6 alkyl amino, di-C_1-C_6 alkyl amino, and C_1-C_6 alkoxy, O-$(CH_2)_{0-3}$-C_3-C_6 carbocyclyl, O-$(CH_2)_{0-3}$-heterocyclyl comprising one or two 3- to 6-membered rings and 1 to 4 heteroatoms selected from N, O, and S, O-$(CH_2)_{0-3}$-C_6-C_{10} aryl, O-$(CH_2)_{0-3}$-heteroaryl comprising one or two 5- or 6-membered rings and 1 to 4 heteroatoms selected from N, O, and S,

C_1-C_6 alkyl amino wherein alkyl is optionally substituted with one or more substituents selected from C_1-C_6 alkyl amino, di-C_1-C_6 alkyl amino, and C_1-C_6 alkoxy, di-C_1-C_6 alkyl amino wherein each alkyl is independently optionally substituted with one or more substituents selected from C_1-C_6 alkyl amino, di-C_1-C_6 alkyl amino, and C_1-C_6 alkoxy, OH, amino, NO_2, halogen, CN, =O, $N(R_N)C(O)R_{62}$, $N(R_N)C(O)OR_{62}$, $N(R_N)S(O)_2$-C_1-C_6 alkyl, $N(R_N)S(O)_2$-C_3-C_6 cycloalkyl, $S(O)_{1-2}NH(C_1$-C_6 alkyl), $S(O)_{1-2}N(C_1$-C_6 alkyl)$_2$, $S(O)_{0-2}$-C_1-C_6 alkyl, $C(O)R_{62}$, $C(O)OR_{62}$, $C(O)NR_{63}R_{64}$, $P(=O)(OR_{62})_2$, C_3-C_6 carbocyclyl, heterocyclyl comprising one or two 3- to 6-membered rings and 1 to 4 heteroatoms selected from N, O, and S, C_6-C_{10} aryl, and heteroaryl comprising one or two 5- or 6-membered rings and 1 to 4 heteroatoms selected from N, O, and S, wherein two of the substituent groups, together with the carbon atom(s) to which they are attached, may form C_5-C_6 carbocyclyl or heterocyclyl comprising a 5- or 6-membered ring and 1 or 2 heteroatoms selected from N, O, and S and wherein the carbocyclyl or heterocyclyl is optionally substituted with one or more R_A, and wherein one or more hydrogen atoms in the substituent group may be replaced with one or more deuterium atoms

each R_{61} is independently

C_1-C_6 alkyl optionally substituted with one or more groups independently selected from C_1-C_6 alkyl amino, di-C_1-C_6 alkyl amino, halogen, OH, amino, C_6-C_{10} aryl, and heteroaryl comprising one or two 5- or 6-membered rings and 1 to 4 heteroatoms selected from N, O, and S,

C_1-C_6 alkoxy, C_1-C_6 haloalkoxy, C_1-C_6 alkyl amino, di-C_1-C_6 alkyl amino, OH, amino, NO_2, halogen, CN, =O,

$C(O)R_{62}$, $C(O)OR_{62}$, $C(O)NR_{63}R_{64}$,

L-C_6-C_{10} aryl, L-heteroaryl comprising one or two 5- or 6-membered rings and 1 to 4 heteroatoms selected from N, O, and S, L-C_3-C_6 carbocyclyl, or L-heterocyclyl comprising one or two 4- to 6-membered rings and 1 to 4 heteroatoms selected from N, O, and S, wherein the aryl, heteroaryl, carbocyclyl, or heterocyclyl is optionally substituted with one or more groups independently selected from:

C_1-C_6 alkyl, C_1-C_6 haloalkyl, $(CH_2)_{0-3}$-C_1-C_6 alkoxy optionally substituted with one or more substituents selected from halogen, C_1-C_6 alkyl amino, di-C_1-C_6 alkyl amino, and C_1-C_6 alkoxy, O-$(CH_2)_{0-3}$-C_3-C_6 carbocyclyl, O-$(CH_2)_{0-3}$-heterocyclyl comprising one or two 3- to 6-membered rings and 1 to 4 heteroatoms selected from N, O, and S, O-$(CH_2)_{0-3}$-C_6-C_{10} aryl, O-$(CH_2)_{0-3}$-heteroaryl comprising one or two 5- or 6-membered rings and 1 to 4 heteroatoms selected from N, O, and S, C_1-C_6 alkyl amino wherein alkyl is optionally substituted with one or more substituents selected from C_1-C_6 alkyl amino, di-C_1-C_6 alkyl amino, and C_1-C_6 alkoxy, di-C_1-C_6 alkyl amino wherein each alkyl is independently optionally substituted with one or more substituents selected from C_1-C_6 alkyl amino, di-C_1-C_6 alkyl amino, and C_1-C_6 alkoxy, OH, amino, NO_2, halogen, CN, =O, $N(R_N)C(O)R_{62}$, $N(R_N)C(O)OR_{62}$, $N(R_N)S(O)_2$-C_1-C_6 alkyl, $N(R_N)S(O)_2$-C_3-C_6 cycloalkyl, $S(O)_{1-2}NH(C_1$-C_6 alkyl), $S(O)_{1-2}N(C_1$-C_6 alkyl)$_2$, $S(O)_{0-2}$-C_1-C_6 alkyl, $C(O)R_{62}$, $C(O)OR_{62}$, $C(O)NR_{63}R_{64}$, $P(=O)(OR_{62})_2$, C_3-C_6 carbocyclyl, heterocyclyl comprising one or two 3- to 6-membered rings and 1 to 4 heteroatoms selected from N, O, and S, C_6-C_{10} aryl, and heteroaryl comprising one or two 5- or 6-membered rings and 1 to 4 heteroatoms selected from N, O, and S, wherein two of the substituent groups, together with the carbon atom(s) to which they are attached, may form C_5-C_6 carbocyclyl or heterocyclyl comprising a 5- or 6-membered ring and 1 or 2 heteroatoms selected from N, O, and S and wherein the carbocyclyl or heterocyclyl is optionally substituted with one or more R_A, and wherein one or more hydrogen atoms in the substituent group may be replaced with one or more deuterium atoms,

wherein:

L is absent, or a linker selected from O, $(CR_{L1}R_{L2})_n$, O-$(CR_{L1}R_{L2})_n$, $(CR_{L1}R_{L2})_n$-O, and $S(O)_2$;

each R_{L1} and each R_{L2} is independently H, CH_3, CH_2CH_3, or $CH(CH_3)_2$, or R_{L1} and R_{L2}, together with the carbon atom to which they are attached, may form C(O), C_3-C_6 cycloalkyl, or heterocyclyl comprising a 4- to 6-membered ring comprising and 1 to 3 heteroatoms selected from N, O, and S, wherein one or more hydrogen atoms in any of R_{L1} and R_{L2} may be replaced with one or more deuterium atoms;

each R_A is independently halogen, OH, C_1-C_6 alkyl, C_1-C_6 alkoxy, C_1-C_6 alkyl amino, or di-C_1-C_6 alkyl amino; and

n is 1, 2, or 3; or

two R_{61}, together with the carbon atom(s) to which they are attached, may form C_4-C_{10} carbocyclyl, heterocyclyl comprising one 4- to 6-membered and 1 to 3 heteroatoms selected from N, O, and S, spiro- or fused-heterocyclyl comprising two 4- to 6-membered rings comprising 1 to 4 heteroatoms selected from N, O, and S, or C_6 aryl, wherein the carbocyclyl, heterocyclyl, spiro- or fused-heterocyclyl, or aryl is optionally substituted with one or more groups independently selected from C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_1-C_6 alkoxy, C_1-C_6 haloalkoxy, C_1-C_6 alkyl amino, di-C_1-C_6 alkyl amino, OH, amino, halogen, CN, and =O; and

each R_{62}, each R_{63}, and each R_{64} is independently H, C_1-C_6 alkyl, or C_1-C_6 haloalkyl.

17. The compound of claim 16, wherein each R_{61}" is H.

18. The compound of claim 16 or 17, wherein R_4 and R_7 each is H, and R_5 is H or F.

19. The compound of claim 16 or 17, wherein each R_{61} is independently C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_1-C_6 alkoxy, C_1-C_6 haloalkoxy, OH, or halogen.

20. A compound selected from Table A, Table B and Table C or a pharmaceutically acceptable salt, solvate, prodrug, stereoisomer, or tautomer thereof.

21. A pharmaceutical composition comprising a compound of any one of claims 1-20, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier or excipient.

22. A method of treating or preventing a diseases or disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of any one of claims 1-20, or a pharmaceutically acceptable salt or solvate thereof.